Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Eun-Kyu Kim Hyun-Ah Kim Jae Soo Koh Min Suk Kim Kwan-Il Kim Jong Inn Lee Nan Mo Moon Eunyoung Ko Woo Chul Noh
- چاپ و سال / کشور: 2010
Description
Cross-talk between the estrogen receptor and the mammalian target of rapamycin (mTOR) pathway is one of the mechanisms of endocrine therapy resistance, and the phosphorylated S6 kinase 1(p-S6K1) is known to be a marker of the mTOR pathway activation. The authors assessed the prognostic significance of p-S6K1 according to the hormone receptor (HR) status. The expression of p-S6K1 was evaluated in 304 breast cancer tissues, and the association between its expression and patient outcomes was investigated. Among 197 cases with the HR (?) tumor, 70 (35.5%) were positive for p-S6K1. Most of the patients (97.5%) with the HR (?) tumor received adjuvant endocrine therapy. The expression of p-S6K1 was found to be an independent worse prognosticator affecting overall survival (OS) and breast cancer-specific survival (BCSS) in the HR (?) group (hazard ratio, 2.62; 95% confidence interval [CI], 1.19–5.76; P = 0.017 and hazard ratio, 3.25; 95% CI, 1.20–8.82; P = 0.020, respectively). In the HR (-) group, however, the p-S6K1 expression was not associated with patients’ survival. The expression of p-S6K1 is a worse prognostic factor in patients with HR (?) tumors. These results suggest that the p-S6K1 expression might be a marker for endocrine therapy resistance in patients with HR (?) tumors.
Breast Cancer Res Treat (2011) 126:93–99 DOI 10.1007/s10549-010-1315-z Received: 15 September 2010 / Accepted: 16 December 2010 / Published online: 24 December 2010 Springer Science+Business Media, LLC. 2010
